日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: Analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for ⩾4 years in the N-MOmentum trial

伊奈比珠单抗治疗视神经脊髓炎谱系障碍的长期疗效和安全性:N-MOmentum试验中接受伊奈比珠单抗治疗≥4年的AQP4-IgG血清阳性患者的分析

Rensel, Mary; Zabeti, Aram; Mealy, Maureen A; Cimbora, Daniel; She, Dewei; Drappa, Jorn; Katz, Eliezer

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder

视神经脊髓炎谱系障碍患者接受伊尼利珠单抗治疗的N-MOmentum试验中的残疾结局

Marignier, Romain; Bennett, Jeffrey L; Kim, Ho Jin; Weinshenker, Brian G; Pittock, Sean J; Wingerchuk, Dean; Fujihara, Kazuko; Paul, Friedemann; Cutter, Gary R; Green, Ari J; Aktas, Orhan; Hartung, Hans-Peter; Lublin, Fred D; Williams, Ian M; Drappa, Jorn; She, Dewei; Cimbora, Daniel; Rees, William; Smith, Michael; Ratchford, John N; Katz, Eliezer; Cree, Bruce A C

Sensitivity analysis of the primary endpoint from the N-MOmentum study of inebilizumab in NMOSD

对 inebilizumab 治疗 NMOSD 的 N-MOmentum 研究的主要终点进行敏感性分析

Cree, Bruce Ac; Bennett, Jeffrey L; Kim, Ho Jin; Weinshenker, Brian G; Pittock, Sean J; Wingerchuk, Dean; Fujihara, Kazuo; Paul, Friedemann; Cutter, Gary R; Marignier, Romain; Green, Ari J; Aktas, Orhan; Hartung, Hans-Peter; Williams, Ian M; Drappa, Jorn; She, Dewei; Cimbora, Daniel; Rees, William; Ratchford, John N; Katz, Eliezer

Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus

阿尼弗鲁单抗(一种抗干扰素-α受体单克隆抗体)用于治疗中重度系统性红斑狼疮

Furie, Richard; Khamashta, Munther; Merrill, Joan T; Werth, Victoria P; Kalunian, Kenneth; Brohawn, Philip; Illei, Gabor G; Drappa, Jorn; Wang, Liangwei; Yoo, Stephen

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

Sifalimumab(一种抗干扰素-α单克隆抗体)治疗中重度系统性红斑狼疮:一项随机、双盲、安慰剂对照研究

Khamashta, Munther; Merrill, Joan T; Werth, Victoria P; Furie, Richard; Kalunian, Kenneth; Illei, Gabor G; Drappa, Jorn; Wang, Liangwei; Greth, Warren

Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

在系统性硬化症患者中评估抗CD19单克隆抗体MEDI-551的安全性和耐受性:一项I期、随机、安慰剂对照、递增单剂量研究

Schiopu, Elena; Chatterjee, Soumya; Hsu, Vivien; Flor, Armando; Cimbora, Daniel; Patra, Kaushik; Yao, Wenliang; Li, Jing; Streicher, Katie; McKeever, Kathleen; White, Barbara; Katz, Eliezer; Drappa, Jorn; Sweeny, Sarah; Herbst, Ronald

A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-α monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients

一项评估抗IFN-α单克隆抗体sifalimumab的1b期临床试验显示,该抗体能够靶向中和皮肌炎和多发性肌炎患者血液中的I型IFN特征。

Higgs, Brandon W; Zhu, Wei; Morehouse, Chris; White, Wendy I; Brohawn, Philip; Guo, Xiang; Rebelatto, Marlon; Le, Chenxiong; Amato, Anthony; Fiorentino, David; Greenberg, Steven A; Drappa, Jorn; Richman, Laura; Greth, Warren; Jallal, Bahija; Yao, Yihong

Impaired T cell death and lupus-like autoimmunity in T cell-specific adapter protein-deficient mice

细胞特异性衔接蛋白缺乏的小鼠的 T 细胞死亡受损和狼疮样自身免疫

Jorn Drappa, Lynn A Kamen, Elena Chan, Maria Georgiev, Dalit Ashany, Francesc Marti, Philip D King